Video

William G. Wierda on the Treatment of CLL

Author(s):

William G. Wierda

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

William G. Wierda, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the treatment of chronic lymphocytic leukemia (CLL). CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals in early November.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Related Content
Illustration of blood cells.
November 20th 2024

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

Ryan Scott
The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of woman with brown hair.
November 19th 2024

Newer Therapies for Acute Lymphoblastic Leukemia May Reduce Side Effects

Spencer Feldman Darlene Dobkowski, MA
New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Image of bald man.
November 18th 2024

How Circulating Tumor Cell Count Can Inform Prostate Cancer Treatment

Alex Biese
An expert explained how circulating tumor cell count can identify possible clinical trial participants.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.